Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Hisamitsu Pharmaceutical Stories

2014-04-01 20:21:21

DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/sjg3pf/hormone) has announced the addition of the "Concise Analysis of the International Hormone Replacement Therapy (HRT) Analysis 2014" [http://www.researchandmarkets.com/research/sjg3pf/hormone ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report analyzes the worldwide markets for Hormone Replacement Therapy...

2013-10-29 23:21:37

Reportbuyer.com just published a new market research report: Drug Delivery Technologies: Commercial Prospects 2013-2023. London (PRWEB) October 29, 2013 Report Details Drug delivery technology - discover technological and commercial prospects What does the future hold for drug delivery technologies? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions. Many commercial opportunities for improved drug delivery exist. You discover sales...

2013-06-28 20:22:22

Brisdelle(TM) is the first and only FDA-approved nonhormonal therapy clinically proven to treat moderate to severe menopausal vasomotor symptoms MIAMI, FL and NEW YORK, NY, June 28, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Brisdelle(TM) low-dose paroxetine capsules, 7.5 mg/day, for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, commonly referred to as hot...

2013-03-04 20:22:19

MIAMI, FL and NEW YORK, NY, March 4, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee voted 10 to 4 that the overall risk/benefit profile of low-dose mesylate salt of paroxetine (LDMP; 7.5 mg/day) is not acceptable to support approval. LDMP is an investigational nonhormonal treatment specifically developed for moderate to severe vasomotor symptoms (VMS) associated with...

2013-01-29 08:30:00

MIAMI and NEW YORK, Jan. 29, 2013 /PRNewswire/ -- Noven Pharmaceuticals, Inc., the manufacturer of Vivelle-Dot(® )(estradiol transdermal system), today announced the availability of Minivelle(TM) (estradiol transdermal system) by prescription in U.S. pharmacies. On October 29, 2012, the U.S. Food and Drug Administration (FDA) approved Minivelle(TM) for the treatment of moderate to severe vasomotor symptoms due to menopause, commonly known as hot flashes and night sweats....

2012-11-12 16:25:51

MIAMI, FL and NEW YORK, NY, Nov. 12, 2012 /PRNewswire/ -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that its New Drug Application (NDA) for low-dose mesylate salt of paroxetine (LDMP; 7.5 mg) for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA's...

2010-05-24 07:00:00

TORRANCE, Calif., May 24 /PRNewswire/ -- Hisamitsu, a world leader in the manufacture of external pain relieving drugs, announced the release of two products for the American market--SALONPAS® PAIN RELIEF PATCH and ARTHRITIS PAIN. (Photo: http://www.newscom.com/cgi-bin/prnh/20100524/LA09424) Both SALONPAS® PAIN RELIEF PATCH and ARTHRITIS PAIN are the first and only FDA approved over-the-counter pain relief patches on the market today....